tirzepatide surmount-1 nejm 2022 weight loss percent For the first time, and semaglutide were put in the same trial. SURMOUNT-5. Phase 3b RCT. 751 adults with obesity, no diabetes. 72 weeks. Both drugs at maximum tolerated dose. The Read now: The SURPASS-EARLY trial
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
00656-2/asset/09a3e122-d7af-44ed-abbd-db334fe4ca36/main.assets/gr3.jpg)





















:max_bytes(150000):strip_icc()/GettyImages-2169095535-f8d8276415dd4300a867a1f8b7de098f.jpg)





